Eupraxia Pharmaceuticals (TSE:EPRX)
TSX:EPRX
EPRX Stock Chart & Stats
C$9.46
C$0.00(0.00%)
At close: 4:00 PM EST
C$9.46
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$4.07 - C$12.86
Previous CloseN/A
Volume2.50K
Average Volume (3M)53.43K
Market Cap
C$587.14M
Enterprise ValueC$165.08M
Total Cash (Recent Filing)C$80.42M
Total Debt (Recent Filing)C$154.08K
Price to Earnings (P/E)―
Beta1.01
Next Earnings
May 07, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding61,503,180
10 Day Avg. Volume45,847
30 Day Avg. Volume53,430
Financial Highlights & Ratios
PEG Ratio-5.41
Price to Book (P/B)5.04
Price to Sales (P/S)0.00
P/FCF Ratio-13.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$20.50Price Target Upside116.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.96
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And DurabilityUpdated high-dose clinical data show strong symptom and tissue improvements after a single administration, supporting the potential for durable effects and infrequent dosing that could differentiate the therapy from current options.
Commercial Opportunity And Analyst CoverageAnalyst initiation with an Outperform rating and active KOL engagement reflect belief in a larger addressable market and commercial upside if randomized topline results confirm early clinical promise.
Safety ProfileLocalized delivery via the DiffuSphere platform has demonstrated a clean safety profile with no serious steroid-related signals and no observed candidiasis, suggesting a favorable safety window for chronic use.
Bears Say
Drug Delivery ReliabilityInitial catheter clogging that reduced delivered drug in early cohorts raises concerns about dosing consistency and device or formulation reliability that could complicate development.
Financing And Dilution RiskA recent equity financing combined with higher projected operating expenses increases dilution risk and may pressure near-term valuation despite continued program funding.
Small Trial SizesSmall patient cohorts in early studies limit the statistical strength of efficacy and durability findings, creating uncertainty until larger randomized trials validate the observed effects.
Eupraxia Pharmaceuticals News
EPRX FAQ
What was Eupraxia Pharmaceuticals’s price range in the past 12 months?
Eupraxia Pharmaceuticals lowest stock price was C$4.07 and its highest was C$12.86 in the past 12 months.
What is Eupraxia Pharmaceuticals’s market cap?
Eupraxia Pharmaceuticals’s market cap is C$587.14M.
When is Eupraxia Pharmaceuticals’s upcoming earnings report date?
Eupraxia Pharmaceuticals’s upcoming earnings report date is May 07, 2026 which is in 28 days.
How were Eupraxia Pharmaceuticals’s earnings last quarter?
Eupraxia Pharmaceuticals released its earnings results on Mar 13, 2026. The company reported -C$0.424 earnings per share for the quarter, missing the consensus estimate of -C$0.208 by -C$0.216.
Is Eupraxia Pharmaceuticals overvalued?
According to Wall Street analysts Eupraxia Pharmaceuticals’s price is currently Undervalued.
Does Eupraxia Pharmaceuticals pay dividends?
Eupraxia Pharmaceuticals does not currently pay dividends.
What is Eupraxia Pharmaceuticals’s EPS estimate?
Eupraxia Pharmaceuticals’s EPS estimate is -0.26.
How many shares outstanding does Eupraxia Pharmaceuticals have?
Eupraxia Pharmaceuticals has 61,503,180 shares outstanding.
What happened to Eupraxia Pharmaceuticals’s price movement after its last earnings report?
Eupraxia Pharmaceuticals reported an EPS of -C$0.424 in its last earnings report, missing expectations of -C$0.208. Following the earnings report the stock price went down -0.588%.
Which hedge fund is a major shareholder of Eupraxia Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:EPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eupraxia Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$20.50 (116.70% Upside)
C$20.50 (116.70% Upside)
Insider Transactions
Bought Shares
Worth C$2.9M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
135.71%
12-Months-Change
Fundamentals
Return on Equity
-59.46%
Trailing 12-Months
Asset Growth
-5.79%
Trailing 12-Months
Company Description
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
EPRX Stock 12 Month Forecast
Average Price Target
C$20.50
▲(116.70% Upside)
Technical Analysis
―
Entheon Biomedical
―
Bright Minds Biosciences
―
MYND Life Sciences
―
Mindbio Therapeutics Corp.
―
Options Prices
Currently, No data available
---